Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.10)
# 539
Out of 5,046 analysts
490
Total ratings
50%
Success rate
13.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Buy | $57 → $45 | $21.47 | +109.59% | 27 | Oct 31, 2025 | |
| ARGX argenx SE | Maintains: Buy | $774 → $915 | $818.50 | +11.79% | 41 | Oct 31, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $115 → $232 | $198.76 | +16.72% | 26 | Oct 16, 2025 | |
| CABA Cabaletta Bio | Reiterates: Buy | $16 | $3.61 | +343.21% | 27 | Oct 10, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $78.62 | +1.76% | 35 | Oct 8, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Neutral | $1 | $1.26 | -20.63% | 18 | Sep 30, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $19.99 | +0.05% | 21 | Sep 18, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $30.70 | +49.84% | 25 | Sep 9, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Buy | $31 → $34 | $28.93 | +17.53% | 2 | Sep 8, 2025 | |
| IMVT Immunovant | Reiterates: Buy | $35 | $24.68 | +41.82% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $9.32 | +50.21% | 18 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $4.05 | +72.84% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $30 | $17.20 | +74.42% | 15 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $20 | $6.46 | +209.60% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $86.22 | +36.86% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $43.50 | +86.21% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $41.92 | +26.43% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.68 | +316.67% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $23.63 | +43.88% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $25.31 | -24.93% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.96 | +512.24% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.02 | +496.03% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $14.67 | +2.25% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.20 | +19.05% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.85 | +42,252.94% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.19 | +740.34% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $171.82 | +5.92% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $8.13 | +130.77% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $42.06 | -57.20% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $20.48 | -60.94% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $21.38 | +143.22% | 2 | Jun 11, 2019 |
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $21.47
Upside: +109.59%
argenx SE
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $818.50
Upside: +11.79%
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $115 → $232
Current: $198.76
Upside: +16.72%
Cabaletta Bio
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $3.61
Upside: +343.21%
Protagonist Therapeutics
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $78.62
Upside: +1.76%
Outlook Therapeutics
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $1.26
Upside: -20.63%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $19.99
Upside: +0.05%
Alkermes
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $30.70
Upside: +49.84%
Rapport Therapeutics
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $34
Current: $28.93
Upside: +17.53%
Immunovant
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $24.68
Upside: +41.82%
Sep 3, 2025
Reiterates: Buy
Price Target: $14
Current: $9.32
Upside: +50.21%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $4.05
Upside: +72.84%
Aug 12, 2025
Maintains: Buy
Price Target: $54 → $30
Current: $17.20
Upside: +74.42%
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.46
Upside: +209.60%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $86.22
Upside: +36.86%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $43.50
Upside: +86.21%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $41.92
Upside: +26.43%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.68
Upside: +316.67%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $23.63
Upside: +43.88%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $25.31
Upside: -24.93%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $1.96
Upside: +512.24%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $3.02
Upside: +496.03%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $14.67
Upside: +2.25%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $4.20
Upside: +19.05%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.85
Upside: +42,252.94%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.19
Upside: +740.34%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $171.82
Upside: +5.92%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $8.13
Upside: +130.77%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $42.06
Upside: -57.20%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $20.48
Upside: -60.94%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $21.38
Upside: +143.22%